Kadcyla Approval History
- FDA approved: Yes (First approved February 22nd, 2013)
- Brand name: Kadcyla
- Generic name: ado-trastuzumab emtansine
- Company: Genentech, Inc.
- Treatment for: Breast Cancer
Kadcyla (ado-trastuzumab emtansine) is a HER2-targeted antibody and microtubule inhibitor conjugate indicated for the treatment of patients with HER2-positive, metastatic breast cancer.
FDA Approval History for Kadcyla
|Feb 22, 2013||FDA Approves Kadcyla for Late-Stage Breast Cancer|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.